Markets:

Overview

News

Currencies

International

Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

5.675 +0.474 (+9.12%)

Streaming Delayed Price Updated: 10:29 AM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

December 04, 2025

As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Should You Invest in This Under-the-Radar Weight Loss Stock? ↗

November 30, 2025

This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon?

Via The Motley Fool

Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review ↗

November 28, 2025

Via Stocktwits

Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat ↗

November 20, 2025

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

Via Benzinga

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark ↗

August 18, 2025

Via Stocktwits

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

A Glimpse of Vanda Pharma's Earnings Potential ↗

May 06, 2025

Via Benzinga

Which stocks are moving on Tuesday? ↗

November 18, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Top movers in Tuesday's session ↗

November 18, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗

November 18, 2025

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 18, 2025

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts ↗

February 18, 2025

Via Benzinga

This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗

November 05, 2025

Via Benzinga

This Trex Company Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗

November 05, 2025

Via Benzinga

VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Reports Q3 2025 Earnings Miss on Revenue, Beat on EPS ↗

October 29, 2025

Vanda Pharma's Q3 2025 results show a revenue miss but a smaller-than-expected loss. The stock fell as strong Fanapt sales growth was offset by investor focus on the top-line shortfall.

Via Chartmill

Topics Earnings

Jim Cramer Calls Cameco A Good Company, Recommends Buying This Financial Stock ↗

October 27, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital and Vanda Pharmaceuticals.

Via Benzinga

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts ↗

January 28, 2025

Via Benzinga

AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗

September 30, 2025

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas.

Via Benzinga

Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals” ↗

August 21, 2025

The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety.

Via Stocktwits

Topics Retirement

Vanda (VNDA) Q2 Revenue Rises 4% ↗

August 01, 2025

Via The Motley Fool

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 23, 2025

Via Benzinga

Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals ↗

April 01, 2025

Via Benzinga

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

February 03, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate ↗

January 16, 2025

FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process.

Via Benzinga

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

December 16, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst ↗

November 01, 2024

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology.

Via Benzinga

Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today ↗

September 19, 2024

A regulator's decision drained the market's enthusiasm for the company.

Via The Motley Fool

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

All News about Vanda Pharmaceuticals Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today